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periosteum explants.
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LONG NON-CODING RNAS IN OSTEOARTHRITIS AND
CHONDROGENESIS
M.J. Barter y, S. Hyatt z, Y. Xu y, D.A. Young y. yNewcastle Univ., Newcastle
upon Tyne, United Kingdom; zCardiff Univ., Cardiff, United Kingdom
Purpose: Since the advent of the genomic age extensive character-
isation of the transcriptome has indicated the abundance of long non-
coding RNAs (lncRNAs) derived from both intergenic and overlapping
protein-coding gene regions. lncRNAs are expressed in a highly tissue-
speciﬁc manner where they function in various aspects of cell biology.
Although only a fraction have been functionally validated lncRNAs have
emerged as key regulators of gene expression, acting through diverse
mechanisms such as the regulation of epigenetic modiﬁcations and by
acting as scaffolds for protein complex formation at gene loci. The
abundance of lncRNAs in cartilage has yet to be established and
accordingly the potential dysregulation of lncRNA expression in carti-
lage pathology is not yet appreciated. Thus the aims of this study are to
illuminate the chondrocyte non-coding transcriptome, examine alter-
ations during osteoarthritis (OA) and establish functions for lncRNAs in
chondrocyte biology.
Methods: RNA sequencing was performed on human articular cartilage
RNA from patients with end-stage hip OA or neck of femur fracture
(NOF). Sequencing was performed by Illumina Genome Analyzer IIx and
reads aligned to the human genome. Bioconductor packages were used
for normalization and to identify differentially expressed transcripts.
lncRNA expression was validated by real-time RT-PCR. Regulation of
lncRNAs was examined during differentiation of human mesenchymal
stem cells (hMSCs) into chondrocytes, in comparison with adipocytes
and osteoblasts. The role of selected lncRNAs following targeted RNA
interference (RNAi) and overexpression was established in humanchondrocytes and during hMSC chondrogenesis. Cartilage assays such
as the DMB glycosaminoglycan assay and hydroxyproline assay were
used in combinationwith RNA expression and histochemical analysis of
cartilage components.
Results: We have identiﬁed the expression of 5000þ lncRNAs in car-
tilage tissue of which 134 appear differentially expressed in OA
compared with NOF (>2 fold change, Benjamini-Hochberg corrected P
value of < 0.05). In addition we have identiﬁed a number of robustly
expressed novel lncRNAs potentially speciﬁc to the chondrocyte
phenotype. Of particular interest are a group of lncRNAs which sur-
round the master chondrocyte transcription factor SOX9 locus. We
conﬁrmed the presence of these novel lncRNAs in chondrocytes and
examined their expression in a number of additional joint tissues and
during differentiation of hMSCs. Many are speciﬁcally induced during
hMSC chondrogenesis correlating with the induction of SOX9 itself.
Depletion of select lncRNAs by RNAi disrupted hMSC chondrogenesis,
concomitant with reduced cartilage gene expression and matrix
component production, indicating an essential role in chondrocyte
biology.
Conclusions: We have characterised the chondrocyte non-coding
transcriptome and identiﬁed a number of novel lncRNAs. Osteoarthritic
tissue exhibits alterations in lncRNA expression and a number of
robustly expressed chondrocyte lncRNAs have critical roles in chon-
drocyte biology. Our ongoing examination into the mechanisms of
lncRNA function will shed light on chondrocyte gene regulation and
provide a greater understanding of mechanisms which may become
disrupted during the development of osteoarthritis.
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INTERLEUKIN-1B IS ESSENTIAL FOR BLOOD-INDUCED CARTILAGE
DAMAGE IN VITRO
L.F. van Vulpen, G. Roosendaal, R.E. Schutgens, S.C. Mastbergen,
F.P. Lafeber. UMC Utrecht, Utrecht, Netherlands
Purpose: Exposure of joint cartilage to blood can occur after joint
trauma, during or after major joint surgery, or due to hemophilia.
This ultimately leads to joint damage, both by direct effects of
blood on cartilage and via synovial inﬂammation. Cartilage
destruction is considered to result from both cartilage matrix-
degrading proteases as well as cartilage-destructive pro-inﬂamma-
tory cytokines such as IL1b. To unravel the role of IL1b in the
pathogenesis of blood-induced cartilage damage, we investigated
whether direct blocking of IL1b speciﬁcally prevents blood-induced
cartilage damage in vitro.
Methods: Full thickness healthy human articular cartilage explants,
obtained post-mortem, were cultured for 4 days in presence or absence
of 50% v/v whole blood. A recombinant human IL1b monoclonal anti-
body (IL1b mAb) was only added during blood exposure in a concen-
tration of 0, 1, 2, 10, 30, or 100 ng/mL. Cartilage matrix proteoglycan
turnover was determined 12 days later to analyse long-term effects.
Moreover, to investigate the direct effects of IL1b mAb on cartilage,
explants were cultured for 4 days in the presence of 10 ng/mL IL1bmAb
in the absence of blood.
Results: Exposure to blood decreased the proteoglycan-synthesis rate
(-62%) and proteoglycan content (-19%), and increased the proteoglycan
release (þ191%, all p < 0.05). Adding IL1bmAb resulted in a dose-
dependent increase of the proteoglycan synthesis rate leading to nor-
malisation at higher concentrations (see ﬁgure A). Moreover, proteo-
glycan release was statistically signiﬁcantly decreased from a
concentration of 3ng/mL and above (see ﬁgure B). Similar, the proteo-
glycan content increased statistically signiﬁcantly upon addition of the
IL1bmAb (3 ng/mL and above; all p < 0.05). In the absence of blood,
IL1bmAb did not have direct effects on cartilage proteoglycan turnover
(p ¼ 0.51).
Conclusions: This study demonstrates that IL1b is a crucial factor in
the development of blood-induced cartilage damage in vitro. Blocking
this pro-inﬂammatory cytokine with a monoclonal antibody protects
cartilage from the damaging effects of blood exposure. Further
research is warranted to investigate the in vivo capacity of IL1b mAb
in prevention and its position as a treatment of hemophilic
arthropathy.
